Health-related quality of life results from the phase III CheckMate 067 study

BACKGROUND: Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Schadendorf, Dirk, Larkin, James, Wolchok, Jedd, Hodi, F. Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, C. Lance, Lao, Christopher, Wagstaff, John, Callahan, Margaret K., Postow, Michael A., Smylie, Michael, Ferrucci, Pier Francesco, Dummer, Reinhard, Hill, Andrew, Taylor, Fiona, Sabater, Javier, Walker, Dana, Kotapati, Srividya, Abernethy, Amy, Long, Georgina V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737813/
https://www.ncbi.nlm.nih.gov/pubmed/28651159
http://dx.doi.org/10.1016/j.ejca.2017.05.031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737813/
https://www.ncbi.nlm.nih.gov/pubmed/28651159
http://dx.doi.org/10.1016/j.ejca.2017.05.031

Ejemplares similares